Menopause represents a highly vulnerable time for women physically, mentally, and socially. The growing body of menopause research among women living with HIV (WLWH) demonstrates that this vulnerable population experiences greater mood and vasomotor symptom burden, which adversely impacts adherence to clinic visits and antiretroviral therapy. Estrogen loss associated with menopause may further enhance the risk for cardiometabolic, cognitive, and bone comorbidities in WLWH. Although there are still more questions than answers in the context of the clinical management of menopause in WLWH, research in this field is evolving, and clinical prevention along with clinician and patient education on this topic can enhance clinical outcomes and quality of life in WLWH globally.
CROI Conference
